Meeting
2021 ASCO Annual Meeting
Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer.
Authors
Ye Guo
Shanghai East Hospital, Shanghai, China
Ye Guo , Weijie Zhang , Jieer Ying , Yanqiao Zhang , Yueyin Pan , Wensheng Qiu , Weiguo Su , Panfeng Tan , Hongyan Yin , Yan Wang , Yang Luo , Hui Zhou , Jin Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Clinical Trial Registration Number
NCT03903705
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2514)
DOI
10.1200/JCO.2021.39.15_suppl.2514
Abstract #
2514
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2022 ASCO Annual Meeting
Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced solid tumors.
First Author: Alberto Bessudo
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Effect of fruquintinib on programmed death receptor-1 blockade antitumor immune responses in colorectal cancer.
First Author: Qingli Li
Poster
2014 ASCO Annual Meeting
A phase Ib/IIa study of NEO-102: A therapeutic antibody for the treatment of advanced pancreatic and colorectal cancer.
First Author: Sandip Pravin Patel